Acutaas Chemicals credit ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
26.526.58.22173.6
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−198−198−241163−55.1
0.02×0.02×0.01×0.32×0.01×
−0.12×−0.12×−0.18×0.24×−0.09×
0.06×0.06×0.04×1.69×0.03×
−0.32×−0.41×−1.04×1.27×−0.45×
135.98×135.98×33.04×18.93×45.71×
1.4%1.5%0.6%24.1%0.6%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ACUTAAS₹3,976.70

Acutaas Chemicals Ltd.

· Pharma & Health
₹ CrorePeersANURASAETHERBLUEJETCAPLIPOINTCONCORDBIOEMCUREJBCHEPHARMERISMcap ₹32,558 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Total Debt3.6216.68.226.526.5
Net Debt-55.1163.3-240.7-198.3-198.3
Total Debt/Equity0.010.320.010.020.02
Net Debt/Equity-0.090.24-0.18-0.12-0.12
Total Debt/EBITDA0.031.690.040.060.06
Net Debt/EBITDA-0.451.27-1.04-0.41-0.32
Interest Coverage (EBIT/Interest)45.7118.9333.04135.98135.98
Total Debt/Total Capital %0.6024.090.621.521.36
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.